Amgen is a global biopharmaceutical company that develops and manufactures innovative biologics and biosimilars across oncology, cardiovascular disease, inflammation, bone health, nephrology, and other therapeutic areas, selling them to physicians, hospitals, pharmacies, and dialysis centers primarily through major pharmaceutical wholesalers. The company generates revenues by selling both proprietary biologic drugs and biosimilar versions of existing medicines to patients whose care is reimbursed through government programs like Medicare and Medicaid, commercial health insurance, pharmacy benefit managers, and international healthcare systems. Amgen faces significant competitive and regulatory headwinds including patent expirations that enable biosimilar and generic competition, reimbursement and pricing pressures from government negotiations and consolidated payers, substantial R&D and manufacturing requirements, and supply-chain dependencies that affect profitability and operational continuity.